^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ER positive + PGR positive

i
Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3, ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
7d
Examining the impact of COVID-19 disruptions on population-based breast cancer screening in Ireland. (PubMed, J Med Screen)
These findings demonstrate signs of a grade change for screen-detected invasive breast cancers early in the pandemic, with recovery evident in 2021, and without an increase in nodal positivity. Future studies are needed to determine the COVID-19 impact on long-term breast cancer outcomes including mortality.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER positive + PGR positive • PGR positive
16d
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes. (PubMed, Clin Breast Cancer)
HER2-low accounted for 70% of the cases and correlated with favorable biological markers. The HER2-low group had a significantly better OS than the HER2-0 group. However, the response to NAC was low in the HER2-low group, and this group had the poorest prognosis among all the non-pCR cases. These findings indicate that HER2-low may have a different biology and prognosis and therefore should be classified as a new entity.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive
27d
Pattern Of Breast Cancer: Experience At Ayub Teaching Hospital, Abbottabad. (PubMed, J Ayub Med Coll Abbottabad)
Our patients presented late: axilla was commonly involved and a third had advanced disease. Screening and community awareness programs may help in early detection. Hormone use for contraception needs to be weighed carefully. Better data collection may help in designing screening and care programs.
Journal
|
PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive
1m
LACOG1018: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (clinicaltrials.gov)
P2, N=43, Completed, Latin American Cooperative Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023
Trial completion • Trial completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive + PGR positive
|
Ibrance (palbociclib) • letrozole
1m
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Feb 2024 --> Jun 2024
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
1m
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (clinicaltrials.gov)
P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Jan 2024 --> Jul 2024
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PI3K (Phosphoinositide 3-kinases)
|
ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation
|
Ibrance (palbociclib) • fulvestrant
2ms
Comprehensive and Accurate Molecular Profiling of Breast Cancer through mRNA Expression of ESR1, PGR, ERBB2, MKI67, and a Novel Proliferation Signature. (PubMed, Diagnostics (Basel))
By assessing the concordance with the results obtained through IHC, we sought to demonstrate the reliability and utility of the kit for precise BC subtyping. Our findings suggest that the kit provides a highly precise and accurate quantitative assessment of BC biomarkers.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • ER positive + PGR positive
2ms
Genomic Alterations of Tumors in HER2-Low Breast Cancers. (PubMed, Int J Mol Sci)
There was a significantly higher frequency of 17.62% (65/369) for PIK3CA_SNA in the HER2-low group than in the HER2-0 group, which had a frequency of only 9.35% (23/246) (p = 0.006). When the called gene alterations in the triple-negative breast cancer (TNBC) group were compared with those in the luminal-like breast cancer group, there was a significantly high frequency of 28.17% (140/497) for ERBB2_SNA in a luminal-like group than in the TNBC group(16.95% (20/118)).We conclude that the early detection of PIK3CA mutations is likely to be important and might help therapeutic decision making in patients with HER2-low tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HER-2 negative • PIK3CA mutation • HER-2 expression • ER positive + PGR positive
2ms
Prognostic Indicators for Radiation-induced Breast Fibrosis (clinicaltrials.gov)
P=N/A; Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2024 --> Jul 2025
Trial primary completion date • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
An image analysis approach to characterize micronuclei differences in different subtypes of breast cancer. (PubMed, Pathol Res Pract)
The study for the first time showed morphometric, architectural and texture related differences amongst MN present in different subtypes of BC. The above may reflect differences in their composition and contents. Further, these differences may point towards the distinct mechanisms involved in the formation of MN in different subtypes of BC that need to be explored further.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive • EGFR positive
3ms
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. (PubMed, Cancers (Basel))
Although older women had poorer OS than younger women, OS was similar after adjusting for KPS, extracranial progression, and systemic therapy; and there was no difference in rates of intracranial PFS, neurological deaths, and LMD in the different age groups. This study suggests that age alone may not play an independent role in treatment-selection and that outcomes for breast cancer patients with BMs and personalized decision-making including other clinical factors should be considered. Future studies are warranted to assess neurocognitive outcomes and other radiation treatment toxicities in older patients.
Journal • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
3ms
COOL-IT: Cryoablation vs Lumpectomy in T1 Breast Cancers (clinicaltrials.gov)
P=N/A, N=256, Not yet recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> Aug 2031 | Trial primary completion date: May 2031 --> Aug 2031
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
3ms
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (clinicaltrials.gov)
P2, N=16, Active, not recruiting, Fox Chase Cancer Center | Phase classification: P2a --> P2 | Trial primary completion date: Dec 2023 --> Jun 2024
Phase classification • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • ER positive + PGR positive
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab)
3ms
TBCRC 050: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (clinicaltrials.gov)
P1/2, N=40, Recruiting, University of Alabama at Birmingham | Phase classification: P1b/2 --> P1/2
Phase classification • Combination therapy • Metastases
|
PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive • EGFR positive
|
Herceptin (trastuzumab) • Zejula (niraparib)
3ms
ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov)
P2, N=252, Recruiting, Guangdong Provincial People's Hospital | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • ER positive + PGR positive
|
gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate
3ms
Development of an International Virtual Multidisciplinary Tumor Board for Breast Cancer in Mongolia. (PubMed, J Surg Res)
This study illustrates the development of an international, virtual, multi-institutional breast cancer MTB and provides insight into challenges and potential interventions to improve breast cancer care in Mongolia.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive
|
Herceptin (trastuzumab)
3ms
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. (PubMed, Curr Oncol)
From the first-generation ADC, trastuzumab emtansine (T-DM1), approved in 2013 for HER2+ breast cancer, to next generation ADCs such as sacituzumab govitecan and trastuzumab deruxtecan, to emerging ADCs on the horizon, we continue to see unparalleled efficacy compared to traditional chemotherapy...Highlighting emerging ADCs and ongoing clinical trials, we will anticipate the changes in the breast cancer treatment paradigm. Lastly, we will outline the available data and current approaches for adverse event management and sequencing strategies for ADCs in clinical practice, including proposed mechanisms of resistance.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • ER positive + PGR positive • EGFR positive
|
Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • datopotamab deruxtecan (DS-1062a)
3ms
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging (clinicaltrials.gov)
P1/2, N=20, Recruiting, University of Alabama at Birmingham | Trial primary completion date: Jun 2025 --> Jun 2028
Trial primary completion date • MRI • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive + PGR positive • PGR positive
3ms
Trial completion date • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden)
|
HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive
|
MSK-IMPACT • OncoPanel™ Assay
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
4ms
SerMa: Seroma of the Mammary Gland (clinicaltrials.gov)
P=N/A, N=2000, Not yet recruiting, University Hospital Augsburg | Trial completion date: Nov 2026 --> Jul 2027 | Initiation date: Jul 2023 --> Jan 2024 | Trial primary completion date: Nov 2023 --> Jul 2024
Trial completion date • Trial initiation date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER positive + PGR positive • PGR positive • PGR negative
4ms
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
4ms
Advancing breast cancer diagnosis with a near-infrared fluorescence imaging smart sensor for estrogen/progesterone receptor detection. (PubMed, Sci Rep)
This non-invasive imaging achieved high-resolution detection without death or serious anaphylactic activity in the animals. Our findings suggest that the reporter system consisting of steroid receptor response elements and near-infrared proteins provides a practical system for identifying biomarkers and advancing cancer diagnosis and therapy.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive
4ms
Enrollment open • Enrollment change
|
PGR (Progesterone receptor)
|
HER-2 positive • ER positive + PGR positive • PGR positive
|
Herceptin (trastuzumab)
4ms
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia. (PubMed, Br J Cancer)
EEF1A2 exhibits angiogenic potential in both normoxic and hypoxic conditions, underscoring its dual role in promoting EMT and angiogenesis, rendering it a promising target for cancer therapy.
Journal
|
PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
ER positive + PGR positive • PGR positive • MYC expression • HIF1A expression
|
Aplidin (plitidepsin)
5ms
Tumor-to-tumor metastasis of an adenocarcinoma to a glioblastoma with review of the literature on tumor-to-tumor metastasis to gliomas. (PubMed, Clin Neuropathol)
The mechanism by which TTM occurs is poorly understood. TTM may be the first presentation of an occult malignancy and warrants thorough clinical, laboratory, and imaging investigation.
Review • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive + PGR positive • IDH wild-type
5ms
Hormone Receptor-Positive Breast Cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the MLH1 Variant 1835del3. (PubMed, J Natl Compr Canc Netw)
Given the patient's family history, this likely represents an uncommon presentation of Lynch syndrome. Physicians should be alert to evaluate patients for targetable genetic variants even in unlikely clinical situations such as the one described here.
Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1)
|
TMB-H • HR positive • HER-2 negative • ER positive + PGR positive • PGR positive
|
Keytruda (pembrolizumab)
5ms
Enrollment open • Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive
|
capecitabine • Kevzara (sarilumab)
5ms
High adherence to Western dietary pattern increases breast cancer risk (an EPIC-Spain study). (PubMed, Maturitas)
Intake of foods such as high-fat dairy products, red and processed meats, refined grains, sweets, caloric drinks, convenience food and sauces might be associated with a higher risk of breast cancer.
Journal • Adherence
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
5ms
Clinical and Epidemiologic Significance of HER2-Low Expression in Breast Cancer in the Pathways Study (SABCS 2023)
Background: A subset of breast cancers (BC) typically classified as HER2-negative do express low levels of the protein and can be responsive to targeted therapy trastuzumab-deruxtecan... In this large prospective study with well annotated epidemiologic, clinical, and outcome data, we observed some clinical and epidemiologic differences between HER2-low and HER2-negative patients, raising the possibility that HER2-low might be a unique biologic entity.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • ER positive + PGR positive • PGR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5ms
Use of DiviTum®TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer (SABCS 2023)
Target accrual is 120 patients. Contact information for people with a specific interest in the trial: Mariya.Rozenblit@yale.edu
Biomarker assay • Compliance • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
5ms
Effect of Radiation Therapy on Survival Outcomes in Elderly ER/PR Positive AJCC Stage T1 Breast Cancer Patients (SABCS 2023)
The current study has demonstrated that more than 54% of these patients received radiation therapy. In univariate analysis, the benefit of adjuvant radiation therapy is more than 9.7% for T1a, T1b, and T1c on 10-year overall survival which is statistically significant. Adjusting for other factors, patients receiving radiation therapy in these elderly population have a 25% less chance of dying as compared to no radiation therapy regardless of AJCC Stage.
Clinical
|
PGR (Progesterone receptor)
|
HR positive • ER positive + PGR positive • PGR positive
5ms
Exceptional long-term disease control on pembrolizumab monotherapy in a patient with TMB-high PMS2-mutated MMR-deficient triple negative breast cancer brain metastasis (SABCS 2023)
She underwent partial mastectomy, axillary dissection, radiation, and received adjuvant anastrozole...She received adjuvant chemotherapy (AC-T) and 1 year of trastuzumab...Two years later, concern for progression from rising tumor markers led to addition of concurrent carboplatin/gemcitabine for 5 cycles...Altogether, this case is a remarkable addition to growing evidence that TMB could be a biomarker for predicting response to ICI therapy and provides an example of ICI efficacy in the setting of BCBM. Further research on additional genomic, clinical, and pathologic features associated with ICI responsiveness is warranted for greater precision in BCBM management.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • PMS2 (PMS1 protein homolog 2)
|
HER-2 positive • TMB-H • ER negative • ER positive + PGR positive • PMS2 mutation • PGR negative
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • carboplatin • gemcitabine • anastrozole
5ms
A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007 (SABCS 2023)
Pts are randomized post-BCS to Arm 1 with breast RT using standard methods (hypo- or conventional-fractionated whole breast RT with/without boost, or APBI) with ≥5 yrs of ET (tamoxifen or AI) or Arm 2 with ≥5 yrs of ET (tamoxifen or AI) alone...Support: U10CA180868, -180822, UG1CA189867, UG1CA189867; Susan G. Komen Foundation (JRW). NCT: 04852887.
P3 data • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive • PGR positive
|
Oncotype DX Breast Recurrence Score®Test
|
tamoxifen
5ms
The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes (SABCS 2023)
HER2-low accounted for 70% of the cases. There were more cases with positive ER/PgR, lower NG, and lower Ki-67 index values in the HER2-low group. The HER2-low group had a significantly better OS than the HER2-0 group.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive
5ms
REaCT-HER TIME: Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (clinicaltrials.gov)
P4, N=20, Active, not recruiting, Ottawa Hospital Research Institute | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive + PGR positive • PGR positive
|
Herceptin (trastuzumab)
5ms
A phase II randomized trial of olaparib administered concurrently with RT vs RT alone for inflammatory breast cancer. (SWOG-Fall 2023)
An interim analysis for futility will be conducted at 50% of the expected IDFS events. Summary Statement For the current status of this study, please refer to the Breast chapter.
Clinical • P2 data • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
|
Lynparza (olaparib)
5ms
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. (SWOG-Fall 2023)
An interim analysis for futility will be conducted at 50% of the expected IDFS events. Summary Statement For the current status of this study, please refer to the Breast chapter.
Clinical • P2 data • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
|
Lynparza (olaparib)
5ms
ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov)
P2, N=252, Not yet recruiting, Guangdong Provincial People's Hospital
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • ER positive + PGR positive
|
gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate
6ms
Biomarkers to Detect Endocrine Therapy Resistance (clinicaltrials.gov)
P2, N=8, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive
6ms
Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India (ESMO Asia 2023)
Conclusions The receipt of HER2-targeted therapy and achievement of pCR significantly impact survival of HER2-positive breast cancer patients treated with neoadjuvant therapy. In patients who achieve pCR baseline disease burden tends to influence survival but not receipt of HER2-targeted therapy.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • ER positive + PGR positive • PGR negative
6ms
Biomarkers to Detect Endocrine Therapy Resistance (clinicaltrials.gov)
P2, N=8, Not yet recruiting, University of Wisconsin, Madison
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER positive + PGR positive